{
  "id": "mcrc-egfr-main",
  "display_name": "mCRC EGFR (Main)",
  "cohort": "mCRC, 2nd Line RAS WT (2024-2025)",
  "insight_type": "Utilization Gap",
  "summary": "Dr. Miller prescribes EGFR inhibitors to 28% of eligible mCRC patients, 42% below NCCN guidance. Closing this gap could yield $173,600/year.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Dr. Miller", "value": 28, "gap": -42, "highlight": true },
      { "name": "Dr. Ahmed", "value": 52, "gap": -18, "highlight": false },
      { "name": "Dr. Kim", "value": 65, "gap": -5, "highlight": false },
      { "name": "Dr. Brown", "value": 78, "gap": 8, "highlight": false }
    ],
    "benchmark": 70,
    "nccn_target": 70
  },
  "financial_impact": {
    "annual_opportunity": "$173,600/year",
    "math": "$173,600/year = 42 patients Ã— $4,133 margin per patient"
  },
  "action_steps": [
    {
      "text": "Flag RAS WT mCRC patients eligible for EGFR therapy",
      "icon": "flag"
    },
    {
      "text": "Start provider alignment discussion with Dr. Miller",
      "icon": "users"
    },
    {
      "text": "Review RAS testing workflow with pathology",
      "icon": "document"
    },
    {
      "text": "Set monitoring alert for 2L EGFR adherence",
      "icon": "alert"
    }
  ]
} 